Login
$LTRN
$0.39 +$0.00 (0.64%) After hours

$LTRN 8-K SEC Filings

Filed On Filing
01 Oct 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On September 25, 2026, Lantern Pharma Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with Nasdaq’s Listing Rule 5550(b)(2), as the market value of lis...

30 Sep 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

This Securities Purchase Agreement (this “Agreement”) is dated as of September 28, 2026, between Lantern Pharma Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including it...

24 Sep 2026 8-K: Regulation FD Disclosure

On September 23, 2026, Lantern Pharma Inc. (the “Company”) hosted a live webinar to discuss the Open-Medicine AI multi-agentic AI platform for drug development.

23 Sep 2026 8-K: Regulation FD Disclosure

Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET

14 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update

03 Aug 2026 8-K: Regulation FD Disclosure

Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine

02 Jun 2026 8-K: Regulation FD Disclosure

On June 1, 2026, Lantern Pharma Inc. (the “Company”) utilized a presentation to assist with the Company’s discussions regarding the Harmonic™ Phase 2 clinical trial for the Company’s product candidate known as LP-300.

15 May 2026 8-K: Results of Operations and Financial Condition

Disciplined Execution Drives 47% Reduction in R&D Spend While Advancing Multiple Clinical Programs, Launching Multi-Agentic AI Platform withZeta.ai Commercially, and Strengthening Balance Sheet with Financing of up to $9.25 Million

14 May 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

This Securities Purchase Agreement (this “Agreement”) is dated as of May 12, 2026, between Lantern Pharma Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its succ...

10 Apr 2026 8-K: Regulation FD Disclosure

On April 9, 2026, Lantern Pharma Inc. (the “Company”) utilized a presentation to assist with the Company’s live demonstration of withZeta.ai, the Company’s multi-agentic AI co-scientist for rare cancer drug discovery, development, and cl...

30 Mar 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Year of Clinical Validation and Strategic Expansion Across Pipeline, AI Platform Advances Towards Commercialization, and Global Trial Milestones

23 Jan 2026 8-K: Regulation FD Disclosure

On January 22, 2026, the Company utilized a presentation to assist with the Company’s discussions during an event hosted by the Company to discuss and demonstrate in a live environment the initial AI tools and multi-agentic system develo...

13 Nov 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates

23 Sep 2025 8-K: Submission of Matters to a Vote of Security Holders

On September 19, 2025, Lantern Pharma Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders, for the purposes of:

13 Aug 2025 8-K: Results of Operations and Financial Condition

Major milestone achieved with successful completion of enrollment for LP-184 Phase 1a clinical trial, with 65 patients enrolled across a range of solid tumors including glioblastoma (GBM); LP-184 is a potential blockbuster drug-candidate...

29 Jul 2025 8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year

Section 2.07 of the By-laws of Lantern Pharma Inc. is deleted in its entirety and replaced with the following:

03 Jul 2025 8-K: Entry into a Material Definitive Agreement

Lantern Pharma Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with ThinkEquity LLC (the “Agent”), as follows:

15 May 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Completion of LP-184 Phase 1a clinical trial enrollment with 62-65 patients across a range of solid tumors expected by end of June 2025.

27 Mar 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Lantern Pharma Provides Business Updates and Fourth Quarter &

10 Jan 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support